Duration of Apixaban in Central Venous Thrombosis

Initial Treatment Phase

• The American College of Cardiology recommends starting apixaban at 10 mg orally twice daily for 7 days as the loading dose regimen, which requires no initial parenteral anticoagulation, demonstrating non-inferiority to conventional enoxaparin/warfarin therapy with significantly lower bleeding rates 1, 2

Maintenance Phase (Standard Dose)

• The American College of Cardiology suggests that provoked central venous thrombosis should be treated for a minimum of 3 months, while unprovoked central venous thrombosis or ongoing risk factors should consider indefinite anticoagulation 1, 2
• The standard dose of apixaban is 5 mg orally twice daily after the initial 7 days for the remainder of the treatment course 4

Extended Treatment Phase (Reduced Dose)

• For patients requiring extended anticoagulation beyond 6 months, the American College of Cardiology recommends reducing to apixaban 2.5 mg orally twice daily for secondary prevention, which minimizes bleeding risk while maintaining efficacy for preventing recurrent VTE 1, 2
• Patients on indefinite therapy should be reassessed at least annually to evaluate the risks and benefits of continuing anticoagulation 1, 2

Special Considerations for Central Venous Thrombosis

• The American College of Cardiology recommends considering indefinite anticoagulation for active malignancy 1, 2

Critical Contraindications and Dose Adjustments

• Apixaban should be avoided in severe renal impairment (CrCl <15 mL/min) and used with caution in CrCl <25 mL/min 4, 5
• Apixaban is contraindicated in patients with intracranial vascular malformations due to high hemorrhage risk 5

Important Pitfalls to Avoid

• Reduced-dose apixaban (2.5 mg twice daily) should not be used before 6 months of full-dose therapy, as this is only validated for extended secondary prevention 1, 2